Since CD8 T cell-mediated immunopathology can occur during viral infections and immune checkpoint blockade therapy for cancer (Iannacone and Guidotti, 2022; Ramos-Casals et al., 2020; Schmidt and Varga, 2018), inhibiting Ly6C2 may help improve patient outcomes in conditions with excessive CD8 T cell activity. This evidence concerns the gene CD8A and viral infectious disease.